Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
 - EconoTimes)
NEW YORK, Jan. 29, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals Inc. (“Tetraphase” or the “Company”) (Nasdaq:TTPH) in the United States District Court for the District of Massachusetts on behalf of a class consisting of all persons or entities who purchased Tetraphase securities between March 5, 2015 and September 8, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the Company and certain insiders issued materially false and misleading statements to investors. In particular, the Complaint alleges that the Company made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of the Company fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015 — a loss of more than 80% in market value.
If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
